[there are ways to get it for much cheaper in Czechia/eastern europe]
2 Likes
The Noble Gas That Reprograms the Brain’s Immune Cells
A noble gas normally used as an anesthetic, xenon, was shown to reprogram the brain’s resident immune cells (microglia) into a protective intermediate state in mouse models of Alzheimer’s disease and tau-driven dementia. A single 40-minute weekly inhalation of 30% xenon compacted amyloid plaques, cut the toxic swollen neurites around them, reduced brain shrinkage, and modestly improved a mouse behavioral marker of cognition. The effect runs through interferon-gamma (IFN-γ) signaling and disappears entirely when microglia are removed, pinning the benefit squarely on immune-cell modulation rather than direct action on neurons. On the strength of these preclinical data, a human Phase 1 safety trial was launched in 2025.
For two decades, Alzheimer’s drug development has chased amyloid plaques with antibodies, and the payoff has been real but modest — a slowing of decline, not a stop. A team from Brigham and Women’s Hospital (Harvard) and Washington University in St. Louis has now taken a very different angle: instead of attacking the plaque, retrain the immune cell that lives beside it.
That cell is the microglia. In a healthy brain it is a quiet housekeeper; in Alzheimer’s it flips into an aggressive, inflammatory “neurodegenerative” state (called MGnD or DAM) that clears some amyloid but also poisons nearby neurons. The holy grail has been to find a “Goldilocks” setting — active enough to eat plaque, calm enough not to damage tissue. The authors report that xenon gas does exactly that, pushing microglia into an intermediate “pre-MGnD” state.
The mechanics are almost disarmingly simple. Xenon is one of the least reactive elements on the periodic table, and — crucially — it crosses the blood-brain barrier freely, which most drugs cannot. Mice engineered to develop amyloid plaques (APP/PS1 and 5xFAD) or tau tangles (P301S on a human APOE4 background) breathed 30% xenon for 40 minutes, weekly, for roughly two months. The treated animals showed tighter, less toxic plaques, fewer dystrophic neurites, less brain atrophy, reduced astrocyte inflammation, and a trend toward better nest-building — a rough proxy for cognition.
The “big idea” is the mechanism. Xenon does not appear to work through its famous target, the NMDA glutamate receptor. Instead it nudges peripheral CD8 T cells to release more IFN-γ, and that cytokine coaxes microglia into the protective pre-MGnD state. Two hard genetic tests back this up: delete the IFN-γ receptor only in microglia, or wipe out brain immune cells with a CSF1R inhibitor, and the benefit vanishes. That is the kind of causal, loss-of-function evidence that separates a real mechanism from a correlation.
The caveats are equally important. These are mouse models that recapitulate features of Alzheimer’s, not the human disease. Xenon did not reduce total soluble or insoluble amyloid, and it did not touch phosphorylated tau — it changed how the immune system responds to pathology, not the pathology’s root load. Behavioral gains were trends, not slam-dunks. Still, because xenon already has a long human safety record as an anesthetic, the translational path is unusually short, and a Phase 1 trial in healthy volunteers began in 2025.
Actionable Insights
Bluntly: there is no at-home biohack here. Xenon is a rare, expensive medical gas administered in a closed-circuit chamber under oxygen monitoring; it is not a supplement, and self-administration of any gas is dangerous. The take-home is conceptual and forward-looking rather than immediately applicable.
What the paper does deliver is a validated mechanistic lever — IFN-γ-driven microglial modulation into a “pre-MGnD” state — that reframes neuroinflammation as something to be tuned, not simply suppressed. This matters because the biohacker instinct to blanket-suppress brain inflammation (broad anti-inflammatories) may be counterproductive; the protective microglial state here is mildly activated, not silenced.
Effect-size magnitudes to anchor expectations (all in mice, versus air-breathing controls):
- Hippocampal volume preserved in tau mice: statistically significant but explicitly described by the authors as “small” (P = 0.021).
- Amyloid plaque load, dystrophic neurites, and astrogliosis: consistently reduced at the P = 0.02–0.05 level — i.e., real but modest, borderline-significant effects, not large ones.
- Total brain amyloid (soluble + insoluble Aβ40/Aβ42): unchanged. The intervention improves plaque quality and neuronal surroundings, not amyloid quantity.
- Cognition proxy (nest-building): a non-significant trend only.
Practical message: monitor the human Phase 1/2 trials before drawing any health conclusions. The realistic near-term magnitude, if it translates at all, looks like a disease-modifying nudge comparable to or additive with anti-amyloid antibodies — not a cure.
Context / Source
- Open Access paper: Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy.
- Authors (lead/corresponding): W. Brandao, N. Jain, Z. Yin (co-first); D. M. Holtzman & O. Butovsky (co-corresponding).
- Institutions: Brigham and Women’s Hospital / Harvard Medical School (Boston, USA) and Washington University School of Medicine (St. Louis, USA), with UC Irvine and General Biophysics LLC.
- Country: United States.
- Journal: Science Translational Medicine (AAAS), Vol. 17, eadk3690, 15 January 2025.
- Impact evaluation: The impact score of this journal is 15.6 (2025 Journal Impact Factor, released June 2026; 5-year JIF 16.8), evaluated against a typical high-end range of 0–60+ for top general-science and medical journals, therefore this is a High impact journal
Xenon Gas an overview.
General information
'Xenon is a heavy gas (symbol Xe; atomic no 54) that is normally present in the atmosphere. It has been used as an anesthetic and as a diagnostic tool in functional neuroimaging [1]."
“Xenon has many characteristics of the ideal anesthetic [2] and has analgesic properties. In addition to its lack of effects on the cardiovascular system (most other anesthetics are negative inotropes), xenon has low solubility, enabling faster induction of anesthesia and faster emergence. Although its high cost limits its use, the development of closed rebreathing systems has led to further interest. It has no effects on the cardiovascular system and has low solubility, enabling faster induction of and emergence from anesthesia.”
'Xenon-enhanced CT scanning in functional neuroimaging is based on the use of stable xenon gas, which is radiodense and lipid-soluble, as an inhaled contrast agent. The patient inhales a mixture of xenon, usually 26–33%, and oxygen for several minutes via a face mask. The inhaled xenon dissolves in the blood and passes into the brain parenchyma. CT scans can be acquired before, during, and after inhalation. Fast spiral CT has improved the capability of this technique."
More details at;
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/xenon